S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:AGTC

Applied Genetic Technologies (AGTC) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.39
▼
$0.39
50-Day Range
$0.37
▼
$0.42
52-Week Range
$0.23
▼
$2.83
Volume
N/A
Average Volume
943,490 shs
Market Capitalization
$26.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33
ProfileAnalyst RatingsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Applied Genetic Technologies MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,763.1% Upside
$7.33 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.65) to ($0.92) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

866th out of 964 stocks

Biological Products, Except Diagnostic Industry

141st out of 159 stocks

See Top Rated MarketRank™ Stocks Here

AGTC stock logo

About Applied Genetic Technologies (NASDAQ:AGTC) Stock

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.


AGTC Stock News Headlines

June 12, 2023 | lse.co.uk
Syncona launches new gene therapy company with GBP96 million funding
June 1, 2023 | msn.com
New AI tool searches genetic haystacks to find disease-causing variants
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
May 17, 2023 | uk.finance.yahoo.com
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction
May 1, 2023 | usnews.com
Applied Technology Center
April 27, 2023 | finance.yahoo.com
AAV Vectors in Gene Therapy Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain
April 21, 2023 | msn.com
World-first technology from biomodal enables reading of genetic and epigenetic information using existing sequencers
April 1, 2023 | nbcnews.com
Elephant in the dining room: Startup creates mammoth meatball
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
March 22, 2023 | bbc.co.uk
Genetic control of metabolism
March 16, 2023 | bbc.co.uk
Genetic testing and cystic fibrosis
January 31, 2023 | yahoo.com
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
January 5, 2023 | thestreet.com
Applied Genetic Technologies (AGTC) Stock Climbs on $124 Million Biogen Deal
November 28, 2022 | finance.yahoo.com
*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*
November 22, 2022 | finance.yahoo.com
*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*
November 15, 2022 | finance.yahoo.com
Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022
November 3, 2022 | finance.yahoo.com
Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022
October 25, 2022 | finance.yahoo.com
Florida investment firm looks to take Cambridge gene therapy startup private
October 24, 2022 | lse.co.uk
Syncona to acquire retinal therapy firm Applied Genetic Technologies
October 23, 2022 | finance.yahoo.com
Syncona to Acquire Applied Genetic Technologies Corporation
October 18, 2022 | markets.businessinsider.com
iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis
September 30, 2022 | msn.com
HC Wainwright & Co. Maintains Buy Rating for Applied Genetic: Here's What You Need To Know
September 23, 2022 | fool.com
Applied Genetic Technologies (NASDAQ: AGTC)
August 29, 2022 | reuters.com
Applied Genetic Technologies Corp
July 26, 2022 | finance.yahoo.com
AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
July 13, 2022 | finance.yahoo.com
AGTC Announces Pricing of $10 Million Underwritten Public Offering
July 12, 2022 | finance.yahoo.com
AGTC Announces Proposed Underwritten Public Offering
See More Headlines
Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Company Calendar

Last Earnings
11/09/2021
Today
9/26/2023
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGTC
CUSIP
N/A
CIK
1273636
Web
www.agtc.com
Phone
(386) 462-2204
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+1,763.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,940,000.00
Net Margins
N/A
Pretax Margin
-21,537.54%
Return on Equity
-192.90%
Return on Assets
-92.54%

Debt

Debt-to-Equity Ratio
0.39
Current Ratio
1.40
Quick Ratio
1.40

Sales & Book Value

Annual Sales
$320,000.00
Price / Sales
83.19
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.26 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
67,632,000
Free Float
64,859,000
Market Cap
$26.62 million
Optionable
Optionable
Beta
1.55
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Ms. Susan B. WasherMs. Susan B. Washer (Age 61)
    Pres, CEO & Director
    Comp: $747.84k
  • Mr. Jonathan I. Lieber M.B.A. (Age 52)
    Chief Financial Officer
    Comp: $533.14k
  • Dr. Susan Schneider M.D. (Age 64)
    Chief Medical Officer
    Comp: $480.32k
  • Dr. Nicholas Muzyczka
    Co-Founder
  • Dr. Barry J. Byrne M.D.
    Ph.D., Co-Founder
  • Dr. William W. Hauswirth
    Co-Founder & Member of Ophthalmology Scientific Advisory Board
  • Dr. Richard Jude Samulski Ph.D.
    Co-Founder
  • Dr. Terence R. Flotte M.D.
    Co-Founder
  • Mr. Gerald Anthony Reynolds
    Chief Accounting Officer, Principal Accounting Officer & Treasurer
  • Dr. Abraham Scaria Ph.D. (Age 63)
    Chief Scientific Officer

Key Competitors

View All Competitors













AGTC Stock - Frequently Asked Questions

Should I buy or sell Applied Genetic Technologies stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGTC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGTC, but not buy additional shares or sell existing shares.
View AGTC analyst ratings or view top-rated stocks.

What is Applied Genetic Technologies' stock price forecast for 2023?

6 brokers have issued 12-month target prices for Applied Genetic Technologies' shares. Their AGTC share price forecasts range from $3.00 to $16.00. On average, they expect the company's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 1,763.1% from the stock's current price.
View analysts price targets for AGTC or view top-rated stocks among Wall Street analysts.

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.05. During the same quarter in the prior year, the firm posted ($0.60) earnings per share.

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $0.39.

How much money does Applied Genetic Technologies make?

Applied Genetic Technologies (NASDAQ:AGTC) has a market capitalization of $26.62 million and generates $320,000.00 in revenue each year. The biotechnology company earns $-68,940,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The official website for the company is www.agtc.com. The biotechnology company can be reached via phone at (386) 462-2204 or via email at david.carey@finnpartners.com.

This page (NASDAQ:AGTC) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -